Skip to main content
. Author manuscript; available in PMC: 2016 Dec 14.
Published in final edited form as: Immunity. 2014 Nov 6;41(5):843–852. doi: 10.1016/j.immuni.2014.10.019

Figure 5. STING signaling is required for effective adaptive immune responses mediated by type I IFN signaling on DCs after radiation.

Figure 5

MC38 tumors established in WT, Tmem173−/−, Cd11cCre+ Ifnarf/f and Ifnarf/f mice were treated locally with one dose of 20Gy. (A) 300μg anti-CD8 mAb was administered i.p. in WT mice every three days for a total of four times starting from the day of radiation. Tumor growth was monitored. (B) Eight days after radiation, tumor draining inguinal lymph nodes (DLNs) were removed from WT and Tmem173−/− mice. Tumor antigen-specific CD8+ T cells function was measured by ELISPOT assays by co-culturing purified CD8+ cells with IFN-γ-treated MC38 tumor cells. (C) 1×1010 viral particles of Ad-null or Ad-IFN-β was administered intratumorally on day 2 after radiation. Tumor DLNs were removed on day 8 after radiation. Isolated CD8+ cells were subjected to ELISPOT assay with the presence of IFN-γ-treated MC38 tumor cells. (D) Tumor growth curves were analyzed in Cd11cCre+ Ifnarf/f and Ifnarf/f mice after radiation. (E) Tumor DLNs from Cd11cCre+ Ifnarf/f and Ifnarf/f mice were removed on day 8 after radiation. ELISPOT assay were performed with purified CD8+ cells and IFN-γ-treated MC38 tumor cells. STING-deficient mice are represented by Tmem173−/−. Representative data are shown from three (A-E) experiments conducted with 5-6 (A and D) or 3-4 (B-C and E) mice per group. Data are represented as mean ± SEM. **P<0.01 and ***P <0.001 (Student's t test). See also Figure S5.